Home / SOST/Sclerostin / Human SOST/Sclerostin Quantikine ELISA Kit

Human SOST/Sclerostin Quantikine ELISA Kit

Catalog #: DSST00
12 Citations Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
DSST00
Control Products Available
QC159: Quantikine Immunoassay Control Set797 Human SOST/Sclerostin
Human SOST/Sclerostin ELISA Standard Curve
2 Images
Product Details
Procedure
Citations (12)
FAQs
Supplemental Products
Reviews
Summary Precision Recovery Linearity Data Examples Product Datasheets Preparation and Storage Background Related Research Areas

Human SOST/Sclerostin Quantikine ELISA Kit Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL)
Sensitivity
3.8 pg/mL
Assay Range
31.3 - 2,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma)
Specificity
Natural and recombinant human SOST
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference
No significant interference observed with available related molecules.

Product Summary

The Quantikine Human SOST immunoassay is a 4.5 hour solid-phase ELISA designed to measure SOST in human cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human SOST and antibodies raised against the recombinant factor. This immunoassay has been shown to accurately quantitate the recombinant human SOST. Results obtained using natural human SOST showed dose response curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for natural SOST.

Precision

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.

Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 20 20 20
Mean (pg/mL) 308 577 1208 315 591 1234
Standard Deviation 6.03 10.5 25.1 25.9 63.8 118
CV% 2 1.8 2.1 8.2 10.8 9.6

Recovery

The recovery of SOST spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 100 91-111
EDTA Plasma (n=4) 95 89-101
Heparin Plasma (n=4) 100 91-108
Serum (n=4) 96 86-112

Linearity

To assess the linearity of the assay, samples containing and/or spiked with high concentrations of human SOST were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human SOST/Sclerostin ELISA Linearity

Scientific Data

N/A Human SOST/Sclerostin ELISA Standard Curve View Larger

Human SOST/Sclerostin ELISA Standard Curve

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Preparation and Storage

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: SOST/Sclerostin

SOST, also known as Sclerostin, is a Cerberus/DAN family BMP antagonist and is an important regulator of bone homeostasis. Inactivating mutations in the SOST gene can cause sclerosteosis and van Buchem disease. SOST is expressed by terminally differentiated cells embedded in mineralized matrix including osteocytes, hypertrophic and prehypertrophic chondrocytes, and tooth cementocytes. Its expression is induced by BMP-2, -4, and -6 and is inhibited by parathyroid hormone (PTH). Its downregulation in osteocytes by physical loading of bone contributes to the mechanical sensor function of osteocytes and the subsequent increase in bone growth. SOST binds to BMP-2, -4, -5, -6, and -7 and inhibits the osteogenic differentiation induced by these BMPs. It inhibits canonical Wnt signaling by binding to LRP-5 and LRP-6 and inhibiting their association with Frizzled receptors. SOST reduces the proliferation of mesenchymal stem cells (MSC) and induces MSC apoptosis. Circulating levels of SOST are elevated in pathologies with bone involvement including low bone mineral density, Paget’s disease, multiple myeloma, and prostate cancer with bone metastases. It is also elevated in advanced chronic kidney disease, alcoholic liver disease, type 2 diabetes, and patients with increased abdominal and gynoid fat.

Entrez Gene IDs:
50964 (Human); 74499 (Mouse)
Alternate Names:
sclerostin; SOST; VBCHsclerosteosis
&#9888; WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
    3. 100 µL Assay Diluent
  3.   Add 100 µL of Assay Diluent to each well.
    4. 50 µL Standard, Control, or Sample
  4.   Add 50 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours on a horizontal orbital microplate shaker.
  5.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.
    6. 200 µL Conjugate
  6.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours on the shaker.
  7.   Aspirate and wash 4 times.
    8. 200 µL Substrate Solution
  8.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes on the benchtop. PROTECT FROM LIGHT.
    9. 50 µL Stop Solution
  9.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human SOST/Sclerostin Quantikine ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

12 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Serum granulocyte-macrophage colony-stimulating factor (GM-CSF) is increased in patients with active radiographic axial spondyloarthritis and persists despite anti-TNF treatment
    Authors: C Papagoras, S Tsiami, A Chrysantho, I Mitroulis, X Baraliakos
    Arthritis Research & Therapy, 2022-08-16;24(1):195.
    Species: Human
    Sample Types: Serum
  2. Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation
    Authors: Y Yu, L Wang, S Ni, D Li, J Liu, HY Chu, N Zhang, M Sun, N Li, Q Ren, Z Zhuo, C Zhong, D Xie, Y Li, ZK Zhang, H Zhang, M Li, Z Zhang, L Chen, X Pan, W Xia, S Zhang, A Lu, BT Zhang, G Zhang
    Nature Communications, 2022-07-22;13(1):4241.
    Species: Mouse, Rat
    Sample Types: Serum
  3. Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy
    Authors: J Rademacher, M Siderius, L Gellert, FR Wink, M Verba, F Maas, LM Tietz, D Poddubnyy, A Spoorenber, S Arends
    Seminars in arthritis and rheumatism, 2022-02-02;53(0):151974.
    Species: Human
    Sample Types: Serum
  4. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study
    Authors: CA Nava-Valdi, JM Ponce-Guar, AM Saldaña-Cr, EG Corona-San, M Ramirez-Vi, EE Perez-Guer, JD Murillo-Sa, B Contreras-, ML Vazquez-Vi, F Gonzalez-P, D Bonilla-La, H Jacobo-Cue, JD Centeno-Va, G Echeverria, S Cerpa-Cruz, MF Alcaraz-Lo, EG Cardona-Mu, M Salazar-Pa, L Gonzalez-L, JI Gamez-Nava
    BioMed Research International, 2021-08-30;2021(0):5567666.
    Species: Human
    Sample Types: Serum
  5. Comparison of insulin-like growth factor-1 and sclerostin levels between premenopausal women with and without diabetes mellitus
    Authors: M Sylvawani, B Setyohadi, D Purnamasar, M Abdullah, MR Kurniawan
    Journal of Taibah University Medical Sciences, 2021-06-11;16(5):719-723.
    Species: Human
    Sample Types: Serum
  6. Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains
    Authors: J Kim, W Han, T Park, EJ Kim, I Bang, HS Lee, Y Jeong, K Roh, J Kim, JS Kim, C Kang, C Seok, JK Han, HJ Choi
    Nat Commun, 2020-10-23;11(1):5357.
    Species: Human
    Sample Types: Cell Culture Supernates
  7. Differences in Osteoimmunological Biomarkers Predictive of Psoriatic Arthritis among a Large Italian Cohort of Psoriatic Patients
    Authors: M Diani, S Perego, V Sansoni, L Bertino, M Gomarasca, M Faraldi, PDM Pigatto, G Damiani, G Banfi, G Altomare, G Lombardi
    Int J Mol Sci, 2019-11-10;20(22):.
    Species: Human
    Sample Types: Serum
  8. Response of Sclerostin and Bone Turnover Markers to High Intensity Interval Exercise in Young Women: Does Impact Matter?
    Authors: R Kouvelioti, N Kurgan, B Falk, WE Ward, AR Josse, P Klentrou
    Biomed Res Int, 2018-11-01;2018(0):4864952.
    Species: Human
    Sample Types: Serum
  9. Negative Association Between Sclerostin and INSL3 in Isolated Human Osteocytes and in Klinefelter Syndrome: New Hints for Testis-Bone Crosstalk
    Authors: A Di Nisio, L De Toni, MS Rocca, M Ghezzi, R Selice, G Taglialavo, A Ferlin, C Foresta
    J. Clin. Endocrinol. Metab., 2018-05-01;0(0):.
    Species: Human
    Sample Types: Serum
  10. Wnt Signaling-Related Osteokines at Rest and Following Plyometric Exercise in Prepubertal and Early Pubertal Boys and Girls
    Authors: P Klentrou, K Angrish, N Awadia, N Kurgan, R Kouvelioti, B Falk
    Pediatr Exerc Sci, 2018-04-23;0(0):1-9.
    Species: Human
    Sample Types: Serum
  11. Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL
    Authors: CC Niu, SS Lin, LJ Yuan, LH Chen, CY Yang, AN Chung, ML Lu, TT Tsai, PL Lai, WJ Chen
    BMC Musculoskelet Disord, 2017-02-02;18(1):61.
    Species: Human
    Sample Types: Serum
  12. Hormonal and systemic regulation of sclerostin
    Authors: Matthew T Drake
    Bone, 2016-12-10;0(0):.
    Species: Human
    Sample Types: Serum

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs
Loading...

Reviews for Human SOST/Sclerostin Quantikine ELISA Kit

There are currently no reviews for this product. Be the first to review Human SOST/Sclerostin Quantikine ELISA Kit and earn rewards!

Have you used Human SOST/Sclerostin Quantikine ELISA Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review